Viking Therapeutics To Present Preclinical Data On Novel Dual GLP-1/GIP Agonists At ObesityWeek 2021

Poster Presentations to Highlight Data From the Company’s Multi-Receptor Agonists in a Rodent Model of Obesity

Viking Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that preclinical data from a series of novel dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors will be presented at ObesityWeek 2021, the annual meeting of The Obesity Society. Results from studies in diet induced obese (DIO) mice will be featured in two poster presentations at the conference, which is being held virtually November 1-5, 2021.

Recommended AI News: AGM Group Announces Significant Order for 25,000 Digital Currency Mining Machines

Details of the poster presentations are as follows:

Poster Presentation #206:

• Title: Novel Co-agonists of GLP-1 and GIP Receptors Produce Robust W********** in a Rodent Model of Obesity
• Presenting Author: Kader Yagiz, Ph.D., Associate Director, Pharmacology, Viking Therapeutics
• Conference Track: Metabolism and Integrative Physiology

Poster Presentation #207:

• Title: Novel Dual Incretin Receptor Agonists Reduce Body Weight and Improve Metabolic Profile in DIO Mice
• Presenting Author: Kader Yagiz, Ph.D., Associate Director, Pharmacology, Viking Therapeutics
• Conference Track: Metabolism and Integrative Physiology

These presentations highlight early results from certain of the company’s internal development efforts, and represent an important potential expansion of the company’s pipeline of novel therapeutics for the treatment of metabolic and endocrine disorders. Further information will be provided in the coming weeks, including details on the data being presented at ObesityWeek 2021.

Recommended AI News: Platform9 Announces SaaS GitOps Engine to Simplify Multicloud Operations and Governance With Latest Kubernetes Release

[To share your insights with us, please write to sghosh@martechseries.com]